- Home
- IMAX vs TVTX Comparison
IMAX vs TVTX Comparison
Compare IMAX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAX
- TVTX
- Stock Information
- Founded
- IMAX 1967
- TVTX 2008
- Country
- IMAX Canada
- TVTX United States
- Employees
- IMAX N/A
- TVTX N/A
- Industry
- IMAX
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAX
- TVTX Health Care
- Exchange
- IMAX Nasdaq
- TVTX Nasdaq
- Market Cap
- IMAX 1.8B
- TVTX 1.5B
- IPO Year
- IMAX 1994
- TVTX N/A
- Fundamental
- Price
- IMAX $32.89
- TVTX $25.60
- Analyst Decision
- IMAX Strong Buy
- TVTX Strong Buy
- Analyst Count
- IMAX 9
- TVTX 16
- Target Price
- IMAX $33.44
- TVTX $35.20
- AVG Volume (30 Days)
- IMAX 795.8K
- TVTX 2.7M
- Earning Date
- IMAX 10-29-2025
- TVTX 10-30-2025
- Dividend Yield
- IMAX N/A
- TVTX N/A
- EPS Growth
- IMAX 52.36
- TVTX N/A
- EPS
- IMAX 0.60
- TVTX N/A
- Revenue
- IMAX $362,475,000.00
- TVTX $333,865,000.00
- Revenue This Year
- IMAX $17.08
- TVTX $83.87
- Revenue Next Year
- IMAX $6.02
- TVTX $40.99
- P/E Ratio
- IMAX $54.87
- TVTX N/A
- Revenue Growth
- IMAX 1.25
- TVTX 87.94
- 52 Week Low
- IMAX $19.19
- TVTX $12.91
- 52 Week High
- IMAX $34.14
- TVTX $28.69
- Technical
- Relative Strength Index (RSI)
- IMAX 62.98
- TVTX 67.53
- Support Level
- IMAX $32.34
- TVTX $23.22
- Resistance Level
- IMAX $34.14
- TVTX $26.53
- Average True Range (ATR)
- IMAX 0.78
- TVTX 1.32
- MACD
- IMAX -0.12
- TVTX -0.07
- Stochastic Oscillator
- IMAX 49.02
- TVTX 80.78
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.